Vaginal seeding may boost neurodevelopment of C-section babies


Monday, 19 June, 2023

Vaginal seeding may boost neurodevelopment of C-section babies

Transferring the mother’s vaginal bacteria onto newborns delivered via caesarean section appears to be beneficial to infants’ early development, according to findings from a recent triple-blind experiment.

Infants born by C-sections tend to have very different gut bacteria composition compared with those born vaginally, according to previous research.

Vaginally born babies receive their early gut bacteria from the mother’s birth canal, while C-section babies’ microbiota are dominated by bacteria found on the mother’s skin, in breastmilk and in the environment.

While the difference tends to disappear as they age, researchers suggest early gut microbiota is associated with the development of an infant’s immune system and could affect their disease risk, including for diabetes, later in life.

This has led to practices like vaginal seeding where mothers would rub C-section newborns with their vaginal fluids. There is, however, limited clinical evidence that vaginal seeding is safe and effective, said Yan He, the paper’s corresponding author at Southern Medical University in Guangzhou, China. He worked with researchers from Icahn School of Medicine at Mount Sinai, USA on the project.

“When we talk about effectiveness, we not only mean whether this intervention might affect the infants’ microbiota but are also interested to see if this intervention could actually improve the infants’ phenotypes, like their neurodevelopment,” He said.

Microbial transfer and mature bacteria

To investigate whether vaginal microbiota seeding works, He and his team rubbed the lips, skin and hands of 32 newborns delivered via C-section with a gauze soaked with their mothers’ vaginal fluids and another 36 newborns with a gauze soaked with saline as blind controls. The mothers were tested in advance to make sure they were free of infections such as sexually transmitted diseases and group B streptococcus.

The team found that newborns who received the microbiota had more gut bacteria found in maternal vaginal fluid 6 weeks after birth, suggesting that maternal vaginal bacteria successfully reached and colonised babies’ guts. Compared with C-section newborns who received saline gauze, babies with microbial transfer had more mature bacteria in their guts at 6 weeks old, similar to babies born vaginally. No infants experienced severe adverse events during the experiment.

Neurodevelopmental benefits

The team also evaluated the babies’ neurodevelopment at 3 months and 6 months after birth using a questionnaire. For example, the researchers would ask the mothers if their babies were able to make simple sounds or perform movements like crawling on their hands and knees. The team found infants who received the seeding scored significantly higher in neurodevelopment at both 3 months and 6 months, and their scores were comparable to those of vaginally born babies.

“We don’t know exactly how early gut bacteria affect their neurodevelopment, but there is some indirect evidence that shows some microbial metabolites are related to conditions,” He said. For example, the team found that babies who received vaginal microbiota seeding had more indolelactic acid, a type of metabolite of several Clostridium bacteria species, in their faeces. Previous research has discovered that indolelactic acid levels are low in people with Parkinson’s disease and Alzheimer’s disease.

Future research

“We’re hoping this study can provide some leads to future research in this field. We want to know if vaginal microbiota seeding has the potential to reduce the risk of neurodevelopmental disorders in children, such as ADHD, ASD and intellectual disabilities,” He said, adding that he and his team plan to carry out long-term clinical trials with larger sample sizes.

“It is somewhat like faecal microbiota transplantation. We need more data to understand this intervention and make it more precise. We may eventually uncover what exactly is beneficial in maternal vaginal microbiota, which could enable us to design therapeutics for all infants born via C-section in the future,” He said.

Image credit: iStockphoto.com/mvaligursky

Related News

High blood pressure costs Australia $1.2bn a year

Australia’s high blood pressure problem costs the country AU$1.2bn a year, with patients...

'Calming agent' could help treat diabetic heart disease

Heart conditions like atherosclerosis, heart attacks and heart failure are said to be the leading...

New public health campaign to improve pregnancy outcomes

The Preterm Birth Prevention campaign 'See, Stop, Scan' aims to promote engagement...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd